TY - JOUR
T1 - Applications of induced pluripotent stem cell technologies in spinal cord injury
AU - Nagoshi, Narihito
AU - Okano, Hideyuki
N1 - Funding Information:
We appreciate the help of Drs Masaya Nakamura, Jun Kohyama, Satoshi Nori, Shinsuke Shibata, Munehisa Shinozaki, Syoichi Tashiro, Kota Kojima, and Shuhei Ito, who are all members of the spinal cord research team in the Department of Physiology, Orthopaedic Surgery and Rehabilitation Medicine, Keio University School of Medicine, Tokyo, Japan. We thank Prof. Douglass Sipp (Keio University) for invaluable comments for the manuscript. This work was supported by Research Center Network for Realization of Regenerative Medicine the Japan Agency for Medical Research and Development (AMED) (to H.O.). H.O. is a founding scientist of SanBio Co. Ltd and K Pharma Inc. N.N. has no conflict of interest.
Publisher Copyright:
© 2017 International Society for Neurochemistry
PY - 2017/6/1
Y1 - 2017/6/1
N2 - Numerous basic research studies have suggested the potential efficacy of neural precursor cell (NPC) transplantation in spinal cord injury (SCI). However, in most such studies, the origin of the cells used was mainly fetal tissue or embryonic stem cells, both of which carry potential ethical concerns with respect to clinical use. The development of induced pluripotent stem cells (iPSCs) opened a new path toward regenerative medicine for SCI. iPSCs can be generated from somatic cells by induction of transcription factors, and induced to differentiate into NPCs with characteristics of cells of the central nervous system. The beneficial effect of iPSC-derived NPC transplantation has been reported from our group and others working in rodent and non-human primate models. These promising results facilitate the application of iPSCs for clinical applications in SCI patients. However, iPSCs also have issues, such as genetic/epigenetic abnormalities and tumorigenesis because of the artificial induction method, that must be addressed prior to clinical use. The selection of somatic cells, generation of integration-free iPSCs, and characterization of differentiated NPCs with thorough quality management are all needed to address these potential risks. To enhance the efficacy of the transplanted iPSC-NPCs, especially at chronic phase of SCI, administration of a chondroitinase or semaphorin3A inhibitor represents a potentially important means of promoting axonal regeneration through the lesion site. The combined use of rehabilitation with such cell therapy approaches is also important, as repetitive training enhances neurite outgrowth of transplanted cells and strengthens neural circuits at central pattern generators. Our group has already evaluated clinical grade iPSC-derived NPCs, and we look forward to initiating clinical testing as the next step toward determining whether this approach is safe and effective for clinical use. This article is part of the mini review series “60th Anniversary of the Japanese Society for Neurochemistry”. (Figure presented.).
AB - Numerous basic research studies have suggested the potential efficacy of neural precursor cell (NPC) transplantation in spinal cord injury (SCI). However, in most such studies, the origin of the cells used was mainly fetal tissue or embryonic stem cells, both of which carry potential ethical concerns with respect to clinical use. The development of induced pluripotent stem cells (iPSCs) opened a new path toward regenerative medicine for SCI. iPSCs can be generated from somatic cells by induction of transcription factors, and induced to differentiate into NPCs with characteristics of cells of the central nervous system. The beneficial effect of iPSC-derived NPC transplantation has been reported from our group and others working in rodent and non-human primate models. These promising results facilitate the application of iPSCs for clinical applications in SCI patients. However, iPSCs also have issues, such as genetic/epigenetic abnormalities and tumorigenesis because of the artificial induction method, that must be addressed prior to clinical use. The selection of somatic cells, generation of integration-free iPSCs, and characterization of differentiated NPCs with thorough quality management are all needed to address these potential risks. To enhance the efficacy of the transplanted iPSC-NPCs, especially at chronic phase of SCI, administration of a chondroitinase or semaphorin3A inhibitor represents a potentially important means of promoting axonal regeneration through the lesion site. The combined use of rehabilitation with such cell therapy approaches is also important, as repetitive training enhances neurite outgrowth of transplanted cells and strengthens neural circuits at central pattern generators. Our group has already evaluated clinical grade iPSC-derived NPCs, and we look forward to initiating clinical testing as the next step toward determining whether this approach is safe and effective for clinical use. This article is part of the mini review series “60th Anniversary of the Japanese Society for Neurochemistry”. (Figure presented.).
KW - cell transplantation
KW - clinical trial
KW - induced pluripotent stem cells
KW - neural precursor cells
KW - spinal cord injury
UR - http://www.scopus.com/inward/record.url?scp=85017362300&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85017362300&partnerID=8YFLogxK
U2 - 10.1111/jnc.13986
DO - 10.1111/jnc.13986
M3 - Review article
C2 - 28199003
AN - SCOPUS:85017362300
SN - 0022-3042
VL - 141
SP - 848
EP - 860
JO - Journal of Neurochemistry
JF - Journal of Neurochemistry
IS - 6
ER -